in vivo News and Research

RSS

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

A leading immunology research institute has validated the long-held and controversial hypothesis that antibodies - usually the "good guys" in the body's fight against viruses - instead contribute to severe dengue virus-induced disease, the La Jolla Institute for Allergy & Immunology announced today. The finding has major implications for the development of a first-ever vaccine against dengue virus, a growing public health threat which annually infects 50 to 100 million people worldwide, causing a half million cases of the severest form.

12 Feb 2010

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.

11 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.

10 Feb 2010

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ open new path to femtomedicine

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ has opened up the path to femtomedicine, an entirely new cancer diagnostics, it was reported today at First Global Congress on NanoEngineering for Medicine and Biology in Houston, TX.

10 Feb 2010

New research suggests closantel drug may be useful in combating river blindness

Scientists at The Scripps Research Institute have discovered a potential new use for the drug closantel, currently the standard treatment for sheep and cattle infected with liver fluke. The new research suggests that the drug may be useful in combating river blindness, a tropical disease that is the world's second leading infectious cause of blindness for humans.

10 Feb 2010

Study shows lactobacillus is effective in improving H. pylori-infected diseases

Helicobacter pylori (H. pylori) are considered to be the most important etiological agents of chronic gastritis. The eradication of H. pyloridepends on the combination of antibiotics and acid suppression drugs.

10 Feb 2010

Fourth-quarter and full-year 2009 results announced by Compugen

Compugen Ltd. today reported financial results for the fourth quarter and year ending December 31, 2009.

9 Feb 2010

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals Corp. today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms’ tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.

9 Feb 2010

Boston researchers identify new mechanism that inhibit tumor growth in mice

A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.

9 Feb 2010

Alnylam Pharmaceuticals receives 'Notice of Allowance' from USPTO

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the “Soutschek and Manoharan” patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.

9 Feb 2010

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

8 Feb 2010

Tβ4 may help treat skeletal muscle disease in Duchenne muscular dystrophy

REGENERX BIOPHARMACEUTICALS, INC. announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with Tβ4, showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. No effects related to muscle function or fibrosis and no adverse reactions were observed in the mice.

6 Feb 2010

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled "Methods for Reprogramming Somatic Cells." Upon issuance, the patent will cover foundational induced pluripotent stem cell (iPSC) technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics.

5 Feb 2010

Study: Generic nifedipine product not bioequivalent to Adalat XL

An extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics.

4 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

Scientists and engineers conduct research on environmental health impacts of nanomaterials

As researchers around the world hasten to employ nanotechnology to improve production methods for applications that range from manufacturing materials to creating new pharmaceutical drugs, a separate but equally compelling challenge exists.

2 Feb 2010

Researchers explore how brain circuitry and learning changes over time

New research shows our brains are a lot more chaotic than previously thought, and that this might be a good thing. Neurobiologists at the University of Maryland have discovered information about how the brain processes sound that challenges previous understandings of the auditory cortex, which had suggested an organization based on precise neuronal maps.

2 Feb 2010

in vivo News and Research

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

Medicinal chemistry paper related to the discovery of CUDC-101 published

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ open new path to femtomedicine

New research suggests closantel drug may be useful in combating river blindness

Study shows lactobacillus is effective in improving H. pylori-infected diseases

Fourth-quarter and full-year 2009 results announced by Compugen

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Boston researchers identify new mechanism that inhibit tumor growth in mice

Alnylam Pharmaceuticals receives 'Notice of Allowance' from USPTO

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Tβ4 may help treat skeletal muscle disease in Duchenne muscular dystrophy

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Study: Generic nifedipine product not bioequivalent to Adalat XL

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Scientists and engineers conduct research on environmental health impacts of nanomaterials

Researchers explore how brain circuitry and learning changes over time

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News